NCT05070260CompletedPhase 2
A Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Parallel Group, Single Dose, Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Acticor Biotech
- Enrollment
- 438
- Locations
- 10
- Primary Endpoint
- Binary Poor Outcome on the mRS defined by a score of 4-6 (versions 0-3)
Study Overview
Brief Summary
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the best standard of care.
Detailed Description
The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the best standard of care.
In all patients, the IVT should have been initiated prior to/at randomization, and in any case within 4.5 hrs post onset of acute ischemic stroke symptoms. IVT should mandatorily be used according to the approved dosing regimen as described in the product information/SmPC/USPI.
Eligible patients will be randomized and the infusion of glenzocimab or of its matching placebo should be administered as soon as possible but no later than two hours from the start of the thrombolytic agent administration. Transferring the patient to the catheterization room should not delay the Investigational Medicinal Product (IMP) administration.
Patients will be randomized in a 1:1 ratio allocation either to glenzocimab or placebo. Randomization will be minimized for factors as follows: (NIHSS <10 vs. ≥ 10), age group (<65, 65-79, ≥80 years), and type of thrombolytic agent (alteplase vs. tenecteplase) in order to balance each treatment group composition.
The allocation of each patient in all centers to an active treatment or placebo will strictly follow the central randomization scheme. Clinical supplies allocation to centers should provide the necessary material so that any eligible patient can receive the assigned treatment. A central randomization system (IRT - Interactive Response Technology) will be used to manage randomization/stratification and drug shipment. The whole process will be handled in a manner that it is blinded for the treatment received to all involved study personnel.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Masking Description
Double blind
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult male or female patients ≥ 18 years (i.e., at least 18 years old at time of randomization)
- •Having given their own written consent, or legal representative consent, and in any case, in strict accordance with country-specific legal requirements,
- •Presenting with an acute disabling ischemic stroke either in the anterior or in posterior circulation, with or without visible occlusion, with a known time of onset, that is ≤ 4.5 hrs
- •Presenting with a pre-IVT NIHSS ≥ 6
- •In whom IVT is or has been initiated, whether or not patients are additionally eligible to mechanical thrombectomy (MT+ IVT), according to the recommendation of the last guidelines (ASA and ESO recommandations),
- •Women of childbearing potential (WOCBP) must have a negative serum/urine pregnancy test at baseline. Women of childbearing potential, i.e., fertile, are defined as women following menarche and until becoming post-menopausal unless permanently sterile, i.e., having undergone hysterectomy, bilateral salpingectomy and bilateral oophorectomy
- •Post-menopausal women defined as not having menses for 12 months without an alternative medical cause. For WOCBP, a highly effective birth control method should be in place that can achieve a failure rate of less than 1% per year that should last for at least 2 months after IMP administration.
- •Birth control methods which may be considered as highly effective in WOCBP include:
- •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (intravaginal, transdermal),
- •progestogen-only hormonal contraception associated with inhibition of ovulation (injectable, implantable)
- •intrauterine device (IUD),
- •intrauterine hormone-releasing system (IUS),
- •bilateral tubal occlusion,
- •vasectomized partner,
- •Birth control methods which may be considered as highly effective for men and that should last for 4 months after IMP administration include:
- •vasectomy,
- •use of condom combined with a highly effective birth control method for their WOCBP partner.
- •Please note that hormonal contraception is a risk factor for thromboembolic events and attention should be called to reconsider it passed the acute stroke phase.
- •Patients affiliated to a health insurance - modality depending on country legal requirement
Exclusion Criteria
- •Coma, or NIHSS >25,
- •Patients < 18 years,
- •Protected adults under guardianship or curatorship,
- •Prior ischemic stroke within the past 3 months,
- •mRS pre-stroke known to be ≥ 2,
- •Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on Baseline Computed Tomography Angiography (CTA) or Magnetic Resonance Imaging (MRI) or with vascular injection (MRA),
- •Significant mass effect with midline shift,
- •Stroke of hemorrhagic origin,
- •Patients likely to require dual antiplatelet therapy (DAPT) within the first 24 hrs after cessation of glenzocimab or placebo infusion for e.g., carotid stenting,
- •Known renal insufficiency (Grades 4-5 - severe or terminal with a creatinine clearance < 30 mL/min using Cockroft formula),
- •Known allergic reaction to contrast agents,
- •Patients under anti-coagulant therapy, except preventative doses of injectable low molecular weight heparin (LMWH),
- •Known ongoing treatment with a mAb,
- •Prior cardiopulmonary resuscitation < 10 days,
- •Childbirth within < 10 days,
- •Seizures at stroke onset if it precludes obtaining an accurate baseline (pre-IVT) NIHSS,
- •Life expectancy (except for stroke) < 3 months,
- •Pregnancy or breastfeeding,
- •Females of childbearing potential not using effective birth control methods,
- •Known current participation in another clinical investigation with experimental drug.
Arms & Interventions
Intravenous glenzocimab (ACT017) 1000 mg
Experimental
Intravenous glenzocimab (ACT017) 1000 mg to be added to thrombolysis +/- mechanical thrombectomy
Intervention: Intravenous glenzocimab (ACT017) 1000 mg (Drug)
Intravenous Placebo
Placebo Comparator
Intravenous Placebo to be added to thrombolysis +/- mechanical thrombectomy
Intervention: Intravenous Placebo (Drug)
Outcomes
Primary Outcomes
Binary Poor Outcome on the mRS defined by a score of 4-6 (versions 0-3)
Time Frame: Day 90
To show the efficacy of glenzocimab vs. placebo, on the "poor outcome" defined as a mRS score of 4-6 (vs 0-3) assessed at Day 90
Secondary Outcomes
- Key Secondary Efficacy Endpoint - mRS(Day 90)
- Mortality(Day 90)
- Change in hematology assessments: Leucocytes(/mm3) at Day 7 or discharge as compared to Baseline(Day 7)
- Ordinal mRS(Day 90)
- Utility Weighted mRS(Day 90)
- All cause mortality(72 hours)
- ICHs(72 hours)
- Neurological Status Change as assessed by NIHSS value compared to pre-IVT value(24 hours)
- mRS(Day 90)
- Change in hematology assessments: Hematocrit at 24 hours at Day 7 or discharge as compared to Baseline(Day 7)
- Recanalization rate(Day 90)
- Cerebral tissue reperfusion(Day 90)
- Infarct volume progression and hemorrhagic transformation(24 hrs)
- Measure of Quality of Life by EuroQol-5 Dimension-5 Level (EQ-5D-5L)(Day 90)
- Incidence of Deaths(Day 90)
- Incidence of Symptomatic intracranial hemorrhages(24 hours)
- Incidence of Non-symptomatic hemorrhages(24 hours)
- Incidence of Adverse Events, SAEs, bleeding-related events, and Treatment-Emergent Adverse Events (TEAEs)(Day 90)
- Change in vital signs (Blood Pressure) at any visit or discharge as compared to Baseline(24 hours)
- Change in vital signs (Heart Rate) at any visit or discharge as compared to Baseline(24 hours)
- Change in hematology assessments: RBC (Red Blood Cell Count) at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: RBC (Red Blood Cell Count) at Day 7 or discharge as compared to Baseline(Day 7)
- Change in hematology assessments: Hemoglobin at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Hemoglobin at Day 7 or discharge as compared to Baseline(Day 7)
- Change in hematology assessments: Hematocrit at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Mean Corpuscular Hemoglobin Volume (MCV) at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Mean Corpuscular Hemoglobin Volume (MCV) at Day 7 or discharge as compared to Baseline(Day 7)
- Change in hematology assessments: Mean corpuscular hemoglobin content (MCHC) at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Mean corpuscular hemoglobin content (MCHC) at Day 7 or discharge as compared to Baseline(Day 7)
- Change in hematology assessments: Corpuscular hemoglobin concentration (CHC) at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Corpuscular hemoglobin concentration (CHC) at Day 7 or discharge as compared to Baseline(Day 7)
- Change in hematology assessments: Leucocytes(/mm3) at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Platelets x 10^9 /L at 24 hours as compared to Baseline(24 hours)
- Change in hematology assessments: Platelets x 10^9 /L at 24 hours at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : SGPT (Sérum Glutamate Pyruvate Transaminase) at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : SGPT at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : SGOT at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : SGOT at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments: LDH at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : LDH at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : Cholesterol at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : Cholesterol at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : Triglycerid at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : Triglycerid at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : Urea at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : Urea at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : Creatinin at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : Creatinin at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : GFR at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : GFR at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : Serum Glucose at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : Serum Glucose at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : D-Dimer at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : D-Dimer at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : Fibrinogen at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : Fibrinogen at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : INR score at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : INR score at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : PT score at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : PT score at Day 7 or discharge as compared to Baseline(Day 7)
- Change biochemistry assessments : aPTT score at 24 hours as compared to Baseline(24 hours)
- Change biochemistry assessments : aPTT score at Day 7 or discharge as compared to Baseline(Day 7)
- Change in dipstick urinalysis assessments: Turbidity at 24 hours as compared to Baseline(24 hours)
- Change in dipstick urinalysis assessments: pH at 24 hours as compared to Baseline(24 hours)
- Change in dipstick urinalysis assessments: Glucose at 24 hours as compared to Baseline(24 hours)
- Change in dipstick urinalysis assessments: Proteins at 24 hours as compared to Baseline(24 hours)
- Change in dipstick urinalysis assessments: Blood at 24 hours as compared to Baseline(24 hours)
- Change in dipstick urinalysis assessments: Leucocytes at 24 hours as compared to Baseline(24 hours)
- Change in dipstick clinical laboratory assessments (urinalysis) at Day 7 or discharge as compared to Baseline(Day 7)
- Change in coagulation parameters (INR, PT, a PTT)(24 hours)
- ECG changes(Day 90)
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Completed
Phase 4
Symptomatic Treatment of Common Cold SymptomsCommon ColdNCT01033526Bayer388
Unknown
Phase 3
Evaluate the Efficacy and Safety of Short-term Administration of SIMDAXAcute Decompensated Heart FailureNCT03555123Yooyoung Pharmaceutical Co., Ltd.112
Withdrawn
Phase 2
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityRelapsing Multiple SclerosisNCT01404117Teva Branded Pharmaceutical Products R&D, Inc.
Completed
Phase 1
To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical GelRosaceaNCT03094403Taro Pharmaceuticals USA1,000
Completed
Phase 3
Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar ExtractionPainNCT05081102Eurofarma Laboratorios S.A.288